Afatinib versus chemotherapy for EGFR mutation-positive NSCLC patients aged ≥65 years:subgroup analyses of LUX-Lung 3 and LUX-Lung 6 | boehringer-ingelheim.jp

PDFをダウンロード (699.23 KB)

Afatinib versus chemotherapy for EGFR mutation-positive NSCLC patients aged ≥65 years:subgroup analyses of LUX-Lung 3 and LUX-Lung 6

View PDFof Afatinib versus chemotherapy for EGFR mutation-positive NSCLC patients aged ≥65 years:subgroup analyses of LUX-Lung 3 and LUX-Lung 6